BNCT for Head and Neck Cancer—History at Our Institution—

DOI Web Site Web Site 16 References
  • Aihara Teruhito
    Proton Medical Research Center, University of Tsukuba Department of Otolaryngology, Kawasaki Medical School
  • Hiratsuka Jyunichi
    Department of Radiation Oncology, Kawasaki Medical School
  • Morita Norimasa
    Department of Otolaryngology, Kawasaki Medical School
  • Kamitani Nobuhiko
    Department of Radiation Oncology, Kawasaki Medical School
  • Suzuki Minoru
    Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University
  • Ono Koji
    Radiation Oncology Research Laboratory, Research Reactor Institute, Kyoto University
  • Kumada Hiroaki
    Proton Medical Research Center, University of Tsukuba
  • Harada Tamotsu
    Department of Otolaryngology, Kawasaki Medical School

Bibliographic Information

Other Title
  • 頭頸部癌に対するホウ素中性子捕捉療法―当施設での歩み―
  • アタマ ケイブガン ニ タイスル ホウソ チュウセイシ ホソク リョウホウ : トウ シセツ デ ノ アユミ

Search this article

Abstract

<p>PURPOSE: Boron neutron capture therapy (BNCT) is among the radiation treatments known to have a selective lethal effect on tumor cells. In this report, we summarize our clinical results for BNCT for the treatment of head and neck cancer at our institution.</p><p>METHODS: We started clinical studies for the treatment of head and neck cancer in 2003. Since then, we have completed the following four clinical studies: (1) an analysis of the accumulation of BPA in the tumor and surrounding normal tissue using an 18FBPA-PET study, (2) a BNCT clinical trial for recurrent head and neck cancer, (3) a BNCT clinical trial for head and neck melanoma, and (4) a BNCT clinical trial for newly diagnosed advanced head and neck cancer. All the patients provided consent, and the study was approved by the medical ethics committees of Kawasaki Medical School and Kyoto University. BNCT was performed in a single fraction using an epithermal beam at the Kyoto University Research Reactor and the Japan Research Reactor 4.</p><p>RESULTS: The 18FBPA-PET study showed no difference in the T/N ratio between an SCC and a non-SCC group. Overall, 83% of the patients had a T/N ratio of more than 2.5. The response rates were more than 80% for all the BNCT clinical studies. Although mild alopecia, xerostomia, and fatigue were observed in all the patients, no severe adverse effects of grade 3 or higher occurred in these patient series.</p><p>CONCLUSIONS: Our preliminary results demonstrated that BNCT is a potentially curative therapy for patients with head and neck cancer. The treatment does not cause any serious adverse effects and can be used regardless of whether the primary tumor has been previously treated.</p>

Journal

References(16)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top